Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bruno Roy is active.

Publication


Featured researches published by Bruno Roy.


Biochimica et Biophysica Acta | 2002

Novel caged fluorescein diphosphates as photoactivatable substrates for protein tyrosine phosphatases.

Qingping Wang; John Scheigetz; Bruno Roy; Michael J. Gresser

We have characterized some novel caged fluorescein diphosphates as photoactivatable, cell-permeable substrates for protein tyrosine phosphatases and explored their usefulness in identifying inhibitors of tyrosine phosphatases. 1-(2-Nitrophenyl)ethyl protected fluorescein diphosphate (NPE-FDP) undergoes rapid photolysis to release FDP upon irradiation with a 450-W UV immersion lamp and its by-product does not inactivate protein tyrosine phosphatase 1B (PTP1B) or alters the viability of cells. The generated FDP from photolysis of NPE-FDP was shown to have exactly the same properties as FDP, which can be used as a PTP substrate in pure enzyme assays. We have also demonstrated that the PTP activity can be measured using NPE-FDP in small droplets. Its advantage as an inert substrate before photolysis allows the possibility of applying nanospray technology in screening and optimizing PTP inhibitors through a large chemical library. Like other caged bioeffectors such as nucleotide and inositol trisphosphate, NPE-FDP is cell-permeable. The NPE-FDP can be photolyzed to generate FDP inside cells, and then can be hydrolyzed by phosphatases to produce fluorescein monophosphate and subsequently to fluorescein. Although Jurkat cells contain high concentrations of CD45, it has not been possible to use FDP as a substrate to measure CD45 activity in the intact cell. This is due to the hydrolysis of FDP by several other cellular phosphatases. However, NPE-FDP can be useful as a cell-permeable substrate for overexpressed phosphatases such as alkaline phosphatase.


Synthetic Communications | 1995

Synthesis of 5-Methanesulfonamido-6-(2,4-Difluorophenylthio)-1-Indanone

John Scheigetz; Robert Zamboni; Bruno Roy

Abstract The ethylene ketal of 5-nitro-6-bromo-1-indanone 6 was prepared via oxidation of N-(6-Bromo-5-indanyl)-acetamide 1. A subsequent mild displacement and elaboration to 6-thiosubstituted-5-amino indanone derivative 10 is also described.


Synthetic Communications | 2000

Synthesis of Fluorescein Phosphorotriesters Using Photolabile Protecting Groups

John Scheigetz; Bruno Roy

Abstract Fluorescein phosphorotriesters 5, each having four identical photoactivatable adducts have been synthesized to investigate their applications as intracellular fluorescence indicators.


Journal of Medicinal Chemistry | 2007

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

Claudio Sturino; Gary P. O'Neill; Nicolas Lachance; Michael R. Boyd; Carl Berthelette; Marc Labelle; Lianhai Li; Bruno Roy; John Scheigetz; Nancy N. Tsou; Yves Aubin; Kevin P. Bateman; Nathalie Chauret; Stephen Day; Jean-François Lévesque; Carmai Seto; Jose H. Silva; Laird A. Trimble; Marie-Claude Carrière; Danielle Denis; Gillian Greig; Stacia Kargman; Sonia Lamontagne; Marie-Claude Mathieu; Nicole Sawyer; Deborah Slipetz; William M. Abraham; Thomas R. Jones; M. McAuliffe; Hana Piechuta


Archive | 2001

Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Marc Labelle; Claudio Sturino; Bruno Roy; Carl Berthelette; Michael Boyd; Nicolas Lachance; John Scheigetz


Bioorganic & Medicinal Chemistry Letters | 2005

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Dwight Macdonald; Anthony Mastracchio; Helene Perrier; Daniel Dube; Michel Gallant; Patrick Lacombe; Denis Deschenes; Bruno Roy; John Scheigetz; Kevin P. Bateman; Chun Li; Laird A. Trimble; Stephen Day; Nathalie Chauret; Deborah A. Nicoll-Griffith; José M. Silva; Zheng Huang; Susana Liu; Diane Ethier; Doug Pon; Eric S. Muise; Louise Boulet; Chi-Chung Chan; Angela Styhler; S. Charleson; Joseph A. Mancini; Paul Masson; David Claveau; Donald W. Nicholson; Mervyn J. Turner


Organic Preparations and Procedures International | 1995

A SYNTHESIS OF 4-α-GUANIDINO-2-DEOXY-2,3-DIDEHYDRO N-ACETYLNEURAMINIC ACID

John Scheigetz; Robert Zamboni; Michael A. Bernstein; Bruno Roy


Bioorganic & Medicinal Chemistry Letters | 2006

Identification of an indole series of prostaglandin D2 receptor antagonists

Claudio Sturino; Nicolas Lachance; Michael Boyd; Carl Berthelette; Marc Labelle; Lianhai Li; Bruno Roy; John Scheigetz; Nancy N. Tsou; Christine Brideau; Elizabeth Cauchon; Marie-Claude Carrière; Danielle Denis; Gillian Greig; Stacia Kargman; Sonia Lamontagne; Marie-Claude Mathieu; Nicole Sawyer; Deborah Slipetz; Gary O’Neill; Zhaoyin Wang; Robert Zamboni; Kathleen M. Metters; Robert N. Young


Bioorganic & Medicinal Chemistry Letters | 2005

Structure–activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP3 antagonists

Michel Belley; Michel Gallant; Bruno Roy; Karine Houde; Nicolas Lachance; Marc Labelle; Laird A. Trimble; Nathalie Chauret; Chun Li; Nicole Sawyer; Nathalie Tremblay; Sonia Lamontagne; Marie-Claude Carrière; Danielle Denis; Gillian Greig; Deborah Slipetz; Kathleen M. Metters; Robert Gordon; Chi-Chung Chan; Robert Zamboni


Bioorganic & Medicinal Chemistry | 2004

Solid phase synthesis of selective caspase-3 peptide inhibitors

Erich L. Grimm; Bruno Roy; Renee Aspiotis; Christopher I. Bayly; Donald W. Nicholson; Dita M. Rasper; Johanne Renaud; Sophie Roy; John Tam; Paul Tawa; John P. Vaillancourt; Steven Xanthoudakis; Robert Zamboni

Researchain Logo
Decentralizing Knowledge